Sign In
Buy HRMY
$35.24
-0.620 (-1.73%)
At Close: Jul 31, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
01:15pm, Thursday, 13'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Such in
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
12:19pm, Tuesday, 11'th Mar 2025
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY). Such investor
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
10:00am, Sunday, 09'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Such inv
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
10:00am, Friday, 07'th Mar 2025
NEW YORK CITY, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Suc
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
01:45pm, Wednesday, 05'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Such inv
Harmony Biosciences to Participate in Upcoming Investor Conferences
08:05am, Tuesday, 04'th Mar 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conference
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
01:15pm, Monday, 03'rd Mar 2025
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY). Such invest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
10:00am, Saturday, 01'st Mar 2025
NEW YORK, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Such inv
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
09:00am, Thursday, 27'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY)Such i
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?
10:45am, Wednesday, 26'th Feb 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Harmony Biosciences Holdings, Inc. (HRMY) Tops Q4 Earnings and Revenue Estimates
09:50am, Tuesday, 25'th Feb 2025
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.45 per share a y
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced a record $201.3 million in net product revenues for the fourth quarter 2024, and full year 202
Harmony Biosciences (HRMY) Upgraded to Strong Buy: Here's Why
01:05pm, Monday, 24'th Feb 2025
Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5 High Earnings Yield Value Stocks to Buy Amid Market Volatility
09:10am, Monday, 24'th Feb 2025
Volatility looms with sticky inflation, a slowing economy and Trump's trade policies. Buy high-earnings-yield stocks like NUS, HRMY, PAHC, DAN and NRG.
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
02:24pm, Wednesday, 19'th Feb 2025
On Wednesday, Harmony Biosciences Holdings, Inc. HRMY received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for excessive daytime sleepiness (EDS) in
